Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04285268
Title Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Rutgers, The State University of New Jersey
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.